Previous 10 | Next 10 |
home / stock / lly / lly articles
CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors, spotlighting significant data and earni...
Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S. healthcare system.&nbs...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Broadcom Inc. (NASDAQ: AVGO) is a "buy." Cramer said although N...
The FDA has approved Eli Lilly And Co's (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of it...
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Freeport-McMoRan Inc. (NYSE: FCX...
Eli Lilly and Company (NYSE: LLY) shares traded higher on Monday. The stock has been trending higher since the company reported third-quarter earni...
Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 30.05% on an annualized basis producing an average annual return of 39.45...
Risk appetite is surging again Thursday on Wall Street, with investors welcoming the Federal Reserve’s decision to keep rates unchanged and F...
Eli Lilly And Co (NYSE: LLY) has reported Q3 sales of $9.49 billion, up 37% Y/Y, beating the consensus of $8.95 billion, driven by growth...
News, Short Squeeze, Breakout and More Instantly...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...